<DOC>
	<DOCNO>NCT01282385</DOCNO>
	<brief_summary>In genesis maintenance PH associate liver cirrhosis two mechanism act synergistically . The first increase hepatic vascular resistance , due part disruption liver structure inherent cirrhosis , increase hepatic vascular tone cause contraction perivascular smooth muscle cell , myofibroblasts hepatic stellate cell , represent 30 % global intrahepatic resistance believe due production Defective nitric oxide ( NO ) . The second mechanism , maintain exacerbates HTP , increase splanchnic blood flow cause increased NO vasodilator level In regard , believe patient compensate liver cirrhosis , portal pressure gradient &gt; 10 mmHg , acute responder betablockers test non-responders , association antifibrotic drug / vasodilator , chronic liver selective May beneficial control portal hypertension</brief_summary>
	<brief_title>Hemodynamic Effect Simvastatin With Beta Blockers Clinical Portal Hypertension</brief_title>
	<detailed_description>This study prospective , randomize , control , double blind , patient meet inclusion criterion give write consent participate study underwent baseline hemodynamic study determine portal pressure gradient ( GPSH ) . During event , assess acute response intravenous administration propranolol . It consider good hemodynamic response decline GPSH &gt; 20 % baseline decrease &lt; 12 mmHg . At conclusion baseline hemodynamic study patient divide 2 treatment group : ) patient respond treatment beta-blockers , treat nadolol dos 40mg/24horas ( increase dose every 2-3 day tolerate , maximum 240 mg / 24 hour . Subsequently randomize two treatment arm , double-blind : a.1 : simvastatin 20 mg capsule , start dos 20 mg / 24 hour , may increase 40 mg accord clinical laboratory tolerance . a.2 : placebo capsule external characteristic similar simvastatin . b ) non-responders treatment beta blocker , carvedilol receive treatment initial dose 6.25 mg / 24 hour , may increase 25mg/dia good clinical tolerance ( HR BP monitoring ) analytical ( renal function electrolyte disturbance ) . Subsequently randomize two treatment arm , double-blind b.1 : simvastatin 20 mg capsule , start dos 20 mg / 24 hour , may increase 40 mg accord clinical laboratory tolerance . b.2 : placebo capsule external characteristic similar simvastatin . In order evaluate long-term hemodynamic effect , patient receive treatment month hemodynamic study repeat completion .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Hypertension , Portal</mesh_term>
	<mesh_term>Adrenergic beta-Antagonists</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<criteria>Liver cirrhosis diagnose previous biopsy clinical , laboratory , ultrasound , PPG &gt; 10 mmHg , Presence large esophageal varix small varix red spot , varix size Pugh C , / gastric fundic varix size , recent gastroscopy ( &lt; 1 month ) Absence previous episode gastrointestinal bleed Written informed consent . Age &lt; 18 &gt; 80 year ; Episode variceal bleeding , Thrombosis splenoportal axis , Hepatocarcinoma , Terminal liver failure ( ChildPugh scale &gt; 13 point ) ; Any comorbidity involve medical drug / life expectancy &lt; 12 month , Severe chronic renal insufficiency ( creatinine &gt; 150 g / L ) , Absolute contraindication allergy treatment statins simvastatin ; Concomitant potent inhibitor CYP3A4 ( eg. , itraconazole , ketoconazole , inhibitor HIV protease , erythromycin , clarithromycin , telithromycin nefazodone ) , Pretreatment ( &lt; 1 month ) lipidlowering simvastatin , Previous episodes rhabdomyolysis ; Contraindication betablockers ( COPD bronchial hyperresponsiveness , aortic stenosis , AV block , intermittent claudication , severe psychosis , bronchial asthma ) , Hypersensitivity beta blocker , Concomitant administration potent inhibitor cytochrome P450 ( quinidine , fluoxetine , paroxetine , propafenone ) Active alcoholic hepatitis , Refusal participate study informed consent claim ; Pretreatment beta blocker nitrate , endoscopic treatment varicose vein portosystemic shunt ; Pregnancy lactation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2011</verification_date>
</DOC>